Cenerimod, a Sphingosine-1-phosphate Receptor Modulator, Versus Placebo in Patients with Moderate-to-severe Systemic Lupus Erythematosus (CARE): an International, Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial
LANCET RHEUMATOLOGY（2025）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要